Back to search results
NCT05421208

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

Active, Not Recruiting
NAAges 18+InterventionalDiagnostic
Vanderbilt University Medical Center
~60 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controlsLevels of inflammatory cytokine ( IL-6) in controlsEffect on inflammation after chronic PNS stimulation

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
IL-6 levels
Measured over Baseline to after 28 days of tVNS stimulation

Conditions

Post-acute COVID-19 Syndrome
Postural Tachycardia Syndrome (POTS)
Long COVID
SARS CoV 2 Infection

Explore related trials

Post-Acute Sequelae of COVID-19Postural Orthostatic Tachycardia Syndrome

NCT05421208

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Vanderbilt University Medical Center

    Nashville, Tennesseeno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Cyndya Shibao, M.D · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Prior RT-PCR-confirmed COVID-19 infection.
Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (\>30 bpm) and chronic (\>3 months) pre-syncopal symptoms.

Exclusion

Heart Disease: Myocardial Infarction, angina, heart failure
History of stroke, or transient ischemic attack
Undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries)
Uncontrolled hypertension defined as persistent blood pressure \>140/90.
Post-menopausal women.
Diabetes Mellitus Type 1 or Type 2. ,
Impaired Hepatic function
Impaired renal function test (eGFR\<60 mL/min/1.73m2).
Ongoing substance abuse.
Mental conditions rendering a subject unable to understand the nature, scope and possible consequences of the study.
History of seizures.
Chronic use of steroids, NSAIDs.
On biologics such as anti-IL6 (omalizumab) and anti-TNF-alpha drugs
Pregnancy or breastfeeding

What this trial measures

  • IL-6 levelsBaseline to after 28 days of tVNS stimulation

    Evaluate immune cell activation in post-COVID-19 POTS and patients with history of COVID-19 infection without sequelae and correlate this with the degree of decreased PNS activity. The primary endpoint is IL-6 levels